A Phase 1 Randomized Blinded Single Dose Comparison of the Safety and Pharmacokinetics of SYN060 Compared to Adalimumab (Humira) From North American and European Sources in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Autoimmune disorders; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Synermore Biologics
- 16 Nov 2018 Status changed from recruiting to completed.
- 09 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Dec 2018.
- 09 Jan 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.